Nanobiotix's NBTXR3 Shows Promising Results in Recurrent Lung Cancer Trial — Nanobiotix S.A.

Event summary

Nanobiotix completed a Phase 1 trial for JNJ-1900 (NBTXR3) in inoperable, recurrent non-small cell lung cancer, with 24 patients completing treatment and no dose-limiting toxicities.
One-year locoregional control rate was 79%, one-year local progression-free survival was 61%, and one-year overall survival was 70%.
The trial demonstrated feasibility of intratumoral injection and potential for clinically meaningful local control at a lower re-irradiation dose.
Additional patient enrollment in the study is planned following encouraging findings presented at the IASLC 2026 World Conference on Lung Cancer.

The big picture

Nanobiotix's NBTXR3 represents a novel approach to enhancing radiotherapy efficacy in radiation-resistant cancers. The Phase 1 results suggest potential for improved local control in recurrent lung cancer, addressing a significant unmet need. The collaboration with Johnson & Johnson positions the therapy for broader clinical evaluation and potential market entry in multiple oncology indications.

What we're watching

Clinical Validation: Whether the promising Phase 1 results will translate into successful outcomes in larger, randomized trials.
Regulatory Pathway: The pace at which Nanobiotix can advance NBTXR3 through subsequent clinical phases and secure regulatory approvals.
Commercial Strategy: How Nanobiotix and Johnson & Johnson will leverage these results to expand the development and commercialization of NBTXR3 across multiple indications.